KQ

Kou Qin

Investment Director at Eisai Innovation

Cambridge, Massachusetts

Overview

Work Experience

  • Managing Director of Investment

    2023 - Current

    • Corporate VC of Eisai, a leading pharma that develops drugs for Alzheimer's disease & cancer • Investing with a strategic focus on aging-related diseases: neurodegeneration, cancer and others

  • Principal of Investment

    2021 - 2022

    • Investing in breakthrough science, platforms and proven teams to address unmet medical needs • Enabling win-win partnerships among portfolio companies, Eisai and collaborating pharma/VC firms

  • Investor

    2024

    eGenesis is revolutionizing human organ xenotransplantation by providing CRISPR-edited, humanized pig organs.

  • Investor

    2023

    Iambic Therapeutics is pioneering the invention of physics-informed generative AI tools, aimed at drastically accelerating small molecule drug discovery.

  • Board Observer

    2023

    Hyku Biosciences is pioneering the next generation of high precision covalent medicine by focusing non-cysteine amino acids (H,Y,K...) of "undruggable" targets.

  • Investor

    2023

    Tune Therapeutics is a global leader in developing CRISPR-based epigenome editing therapeutics for common diseases. https://www.genengnews.com/news/epigenetic-editing-in-non-human-primates-presented-by-tune-at-asgct/

  • Board Observer

    2022

    RiboX Therapeutics is a circular RNA (circRNA) company, grounded in the pioneering work of its scientific founder Ling-Ling Chen in the biogenesis and functions of circRNA. With its unique protein-coding and non-coding functions, circRNA can overcome the current limitations of mRNA therapeutics. https://scholar.google.com/citations?user=0UNkhq4AAAAJ

  • Board Observer

    2022

    Casma Therapeutics is advancing the next generation bio-degradation innovation based on autophagy.

  • Board Observer

    2022

    Delivering RNA drugs non-invasively across the blood-brain barrier (BBB) to treat neurodegenerative diseases. https://ophidion.com/

  • Investor

    2020

    Pyrotech is founded on the seminal work of Shao Feng, which illuminated the mechanism of 'Pyroptosis'. This novel form of cell death controls infection by activating strong immune responses. https://scholar.google.com/citations?user=wLg0PUQAAAAJ

  • Investor

    2021

    Founded by proven entrepreneurs, Travera is using a breakthrough innovation from MIT to measure individual cancer cells’ weight and responses in order to match patients with drugs quickly in real clinics.

Relevant Websites